Showing posts with label Maxygen. Show all posts
Showing posts with label Maxygen. Show all posts
Thursday, September 8, 2011
Maxygen board approves $10 million boost in stock repurchase program
Maxygen Inc. said Thursday its board of directors approved upping the company’s stock repurchase program from $10 million to $20 million.
Thursday, May 5, 2011
Maxygen swings to profit in Q1
Maxygen Inc. on Thursday reported first quarter net income of $1.5 million, or 5 cents a share, compared to a loss in the same period last year of $2 million, or 6 cents a share.
Thursday, March 17, 2011
Astellas to buy out Maxygen interest in joint venture for $76 million
Astellas Pharma Inc. will buy out Maxygen Inc.’s interest in Redwood City joint venture Perseid Therapeutics Inc. for $76 million.
Astellas and Maxygen (NASDAQ: MAXY) of Redwood City set up the joint venture in summer 2009, with Maxygen transferring substantially all of its protein pharmaceutical programs and related assets and R&D personnel to Perseid. It granted Astellas an option to to buy all of Maxygen’s ownership interest in Perseid at exercise prices that increased each quarter until Sept. 18, 2012.
Astellas and Maxygen (NASDAQ: MAXY) of Redwood City set up the joint venture in summer 2009, with Maxygen transferring substantially all of its protein pharmaceutical programs and related assets and R&D personnel to Perseid. It granted Astellas an option to to buy all of Maxygen’s ownership interest in Perseid at exercise prices that increased each quarter until Sept. 18, 2012.
Subscribe to:
Posts (Atom)